67 Jefferson Street
Hartford, CT 06106
Phone: 860 545 4574
Fax: 860 545 4575
Gualberto Ruaño, President & CEO
Genomas is a biomedical company advancing personalized health with revolutionary PhyzioTypeTM systems for DNA-guided diagnosis and prevention of serious side effects induced by cardiovascular, psychiatric, and diabetic medications. The products are being developed in partnership with three leading CT medical institutions, Hartford Hospital, The Institute of Living and The Hospital of Central Connecticut.
PhyzioTypeTM medical management systems will change the current course of treatment. They provide physicians the unprecedented capability to prevent serious side effects based on the patient?s DNA. By comparing side effect risks of drugs in a therapeutic class for each patient and by forewarning doctors of adverse responses that will complicate treatment, PhyzioTypeTM systems eliminate trial and error with DNA- guided medicine. A PhyzioTypeTM system has 3 proprietary components: an ensemble of inherited, stable DNA markers from several genes, a biostatistical algorithm validated in clinical studies for ascertaining the clinical significance of a patient?s DNA marker configuration, and a graphical portal for doctors to select drugs based on an individual?s risk of developing side effects.